UNSPSC 51402307: Enciprazine hydrochloride

This classification denotes an anxiolytic with the molecular formula C23H32N2O6.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YTO3CZ93HM, chemically known as 1-piperazineethanol, 4-(2-methoxyphenyl)-alpha-((3,4,5-trimethoxyphenoxy)methyl)-, dihydrochloride, (+-)- but more generally known as enciprazine hydrochloride, which bears US NIH Compound Identifier 50221. Most nations, for tariff and trade purposes, schedule enciprazine hydrochloride under HS 29335995 and SITC 51576.

As of Q4 2014, ENCIPRAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Enciprazine hydrochloride bears US NLM identifiers UMLS ID C0957736 and NCI Concept Code C87666. SMILES: COC1CCCCC1N2CCN(CC2)CC(COC3CC(C(C(C3)OC)OC)OC)O.CL.CL.

UNSPSC 51402307 Enciprazine hydrochloride is a Commodity code within a pharmaceutical taxonomy, but the recent state and local opportunities posted under this code show little direct alignment with the specific product name. Instead, the solicitations reflect state and local government procurement of pharmaceutical products and pharmacy services more broadly—including naloxone and drug deactivation systems for public health programs, generic multi-source pharmaceuticals and over-the-counter products for cooperative purchasing networks, and direct-to-manufacturer prescription program capabilities. The issuing bodies span county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances managing multi-state pharmaceutical distribution (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local facilities in Minnesota and Oregon). These procurements reflect the range of state and local demand for pharmaceutical supply chain management, public health interventions, and cost-effective generic medication sourcing rather than procurement specific to enciprazine hydrochloride itself.

Recent activity is concentrated in the Southeast and Upper Midwest. Seminole County's IFB 60459723LAS, posted June 30, 2026, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building, response due July 26, 2023, with a two-year initial term and one-year renewal option. The Minnesota Department of Administration's MMCAP RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026, requires proposals by March 26, 2026, and covers state and local facilities in Minnesota and Oregon through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), with contracts effective July 1, 2026. Texas HHS issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription program implementation, signaling foundational market research before a formal RFP. The code's activity shows mixed pharmaceutical procurement approaches—some driven by specific public health needs, others by cooperative network efficiency, and others by manufacturer-direct program development—rather than a coherent commodity focus.